Alendronate sodium demonstrates significant clinical advantages in treating osteoporosis secondary to severe fractures

Abstract

Objective: To investigate the clinical efficacy of alendronate sodium in patients with osteoporosis secondary to severe fractures.

Methods: A total of 102 patients with post-fracture osteoporosis were retrospectively included in this study. The control group (n=45) received standard treatment, while the research group (n=57) was additionally administered alendronate sodium. Bone metabolism markers, pain intensity (assessed by Visual Analogue Scale [VAS]), bone mineral density (BMD), and overall therapeutic efficacy were compared between the two groups. Multivariate logistic regression was performed to identify predictors of therapeutic efficacy.

Results: Compared with the control group, the research group demonstrated significantly greater improvements in bone metabolism markers, VAS scores, BMD, and overall efficacy. Univariate and multivariate logistic regression analyses further identified smoking history, alcohol abuse, and treatment modality as independent risk factors for treatment failure, while elevated serum bone Gla protein (BGP) levels were identified as a protective factor.

Conclusion: Alendronate sodium significantly improves clinical outcomes in treating patients with osteoporosis secondary to severe fractures.

Keywords: Alendronate sodium; bone metabolism; osteoporosis; pain; severe fractures; treatment efficacy.

Figure 1

Comparison of bone metabolism markers between the two groups. A: Pre- and post-treatment CTX-I levels in the control and research groups. B: Pre- and post-treatment NTX-I levels in the control and research groups. C: Pre- and post-treatment BGP levels in the control and research groups. Notes: CTX-I, C-terminal telopeptide of type I collagen; NTX-I, N-terminal telopeptide of type I collagen; BGP, osteocalcin (bone Gla protein). ^aP < 0.05, ^bP < 0.01, in comparison with the pre-treatment level; ^cP < 0.05, when compared with the control group.

Figure 2

Comparison of pain intensity between the two groups. A: Pre- and post-treatment VAS scores for spontaneous pain in the control and research groups. B: Pre- and post-treatment VAS scores for pain during turning over in the control and research groups. C: Pre- and post-treatment VAS scores for pain during weight-bearing in the control and research groups. D: Pre- and post-treatment VAS scores for pain during flexion-extension in the control and research groups. Notes: VAS, Visual Analogue Scale. ^aP < 0.05, ^bP < 0.01, compared to pre-treatment levels; ^cP < 0.05, compared to the control group.